184 related articles for article (PubMed ID: 35361879)
1. Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
Carbone ML; Madonna G; Capone A; Bove M; Mastroeni S; Levati L; Capone M; Ascierto PA; De Galitiis F; D'Atri S; Fortes C; Volpe E; Failla CM
Sci Rep; 2022 Mar; 12(1):5448. PubMed ID: 35361879
[TBL] [Abstract][Full Text] [Related]
2. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.
Carbone ML; Capone A; Guercio M; Reddel S; Silvestris DA; Lulli D; Ramondino C; Peluso D; Quintarelli C; Volpe E; Failla CM
Front Immunol; 2023; 14():1197630. PubMed ID: 37680638
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.
Verkhovskaia S; Di Pietro FR; Mastroeni S; Carbone ML; Abeni D; Morese R; Morelli FM; D'Atri S; Marchetti P; De Galitiis F; Failla CM; Fortes C
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2529-2538. PubMed ID: 34595541
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.
Rao H; Guo Z; Wen X; Zeng X; Wu L; Huang L
Front Oncol; 2022; 12():1099108. PubMed ID: 36713515
[TBL] [Abstract][Full Text] [Related]
5. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion.
Lommerts JE; Bekkenk MW; Luiten RM
Expert Opin Drug Saf; 2021 Aug; 20(8):883-888. PubMed ID: 33896329
[No Abstract] [Full Text] [Related]
6. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
[TBL] [Abstract][Full Text] [Related]
7. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
Willsmore ZN; Harris RJ; Crescioli S; Hussein K; Kakkassery H; Thapa D; Cheung A; Chauhan J; Bax HJ; Chenoweth A; Laddach R; Osborn G; McCraw A; Hoffmann RM; Nakamura M; Geh JL; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Papa S; Barber L; Lacy KE; Karagiannis SN
Front Immunol; 2020; 11():622442. PubMed ID: 33569063
[TBL] [Abstract][Full Text] [Related]
8. Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study.
Hermann N; Maul LV; Ameri M; Traidl S; Ziadlou R; Papageorgiou K; Kolm I; Levesque M; Maul JT; Brüggen MC
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230498
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study.
Guida M; Strippoli S; Maule M; Quaglino P; Ramondetta A; Chiaron Sileni V; Antonini Cappellini G; Queirolo P; Ridolfi L; Del Vecchio M; Cocorocchio E; Di Giacomo AM; Festino L; Merelli B; Occelli M; Brugnara S; Minisini A; Sava S; Tommasi S; De Summa S;
ESMO Open; 2021 Apr; 6(2):100064. PubMed ID: 33711672
[TBL] [Abstract][Full Text] [Related]
10. Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences.
Cohen BE; Manga P; Lin K; Elbuluk N
Am J Clin Dermatol; 2020 Oct; 21(5):669-680. PubMed ID: 32468356
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
Gault A; Anderson AE; Plummer R; Stewart C; Pratt AG; Rajan N
Br J Dermatol; 2021 Aug; 185(2):263-271. PubMed ID: 33393076
[TBL] [Abstract][Full Text] [Related]
12. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
[TBL] [Abstract][Full Text] [Related]
13. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
14. A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors.
Medri M; Savoia F; Foca F; Miserocchi A; Quaglino P; Rubatto M; Gullo G; Nardini C; Panasiti V; DE Tursi M; DI Marino P; Brancaccio G; Giunta EF; Napolitano S; Cinotti E; Brusasco M; Stanganelli I;
Ital J Dermatol Venerol; 2023 Dec; 158(6):437-444. PubMed ID: 38015482
[TBL] [Abstract][Full Text] [Related]
15. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.
Liu RC; Consuegra G; Chou S; Fernandez Peñas P
Clin Exp Dermatol; 2019 Aug; 44(6):643-646. PubMed ID: 30618056
[TBL] [Abstract][Full Text] [Related]
16. Vitiligo-like depigmentation patterns in patients receiving immunotherapy for metastatic melanoma.
Zottarelli F; Giorgione R; Gironi LC; Farinelli P; Sponghini AP; Rondonotti D; Savoia P
Ital J Dermatol Venerol; 2021 Feb; 156(1):97-99. PubMed ID: 30350560
[No Abstract] [Full Text] [Related]
17. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Turiello R; Capone M; Giannarelli D; Morretta E; Monti MC; Madonna G; Mallardo D; Festino L; Azzaro R; Levesque MP; Imhof L; Weide B; Amaral T; Chevrier M; Sucker A; Rutkowski P; Schadendorf D; Lebbe C; Luke JJ; Wistuba-Hamprecht K; Dummer R; Pinto A; Morello S; Ascierto PA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361405
[TBL] [Abstract][Full Text] [Related]
18. Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma.
Kverneland AH; Thorsen SU; Granhøj JS; Hansen FS; Konge M; Ellebæk E; Donia M; Svane IM
Immunooncol Technol; 2023 Dec; 20():100396. PubMed ID: 37810199
[TBL] [Abstract][Full Text] [Related]
19. Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Middleton MR; Hoeller C; Michielin O; Robert C; Caramella C; Öhrling K; Hauschild A
Br J Cancer; 2020 Sep; 123(6):885-897. PubMed ID: 32713938
[TBL] [Abstract][Full Text] [Related]
20. The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.
Teulings HE; Willemsen KJ; Glykofridis I; Krebbers G; Komen L; Kroon MW; Kemp EH; Wolkerstorfer A; van der Veen JP; Luiten RM; Tjin EP
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1086-96. PubMed ID: 25043574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
